Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Prospective Interventional Study of the Tolerability and Efficacy of Oral Harnalidge® OCAS® (Tamsulosin) 0.4 mg in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2 mg

NCT02180789 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT02180789
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02180789 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Prospective Interventional Study of the Tolerability and Efficacy of Oral Harnalidge® OCAS® (Tamsulosin) 0.4 mg in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2 mg
Lead sponsor
Astellas Pharma Inc
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2013
Completion date
January 31, 2015
Enrollment
100 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph)